Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Mesodermal iPSC–derived progenitor cells functionally regenerate cardiac and skeletal muscle
Mattia Quattrocelli, Melissa Swinnen, Giorgia Giacomazzi, Jordi Camps, Ines Barthélemy, Gabriele Ceccarelli, Ellen Caluwé, Hanne Grosemans, Lieven Thorrez, Gloria Pelizzo, Manja Muijtjens, Catherine M. Verfaillie, Stephane Blot, Stefan Janssens, Maurilio Sampaolesi
Mattia Quattrocelli, Melissa Swinnen, Giorgia Giacomazzi, Jordi Camps, Ines Barthélemy, Gabriele Ceccarelli, Ellen Caluwé, Hanne Grosemans, Lieven Thorrez, Gloria Pelizzo, Manja Muijtjens, Catherine M. Verfaillie, Stephane Blot, Stefan Janssens, Maurilio Sampaolesi
View: Text | PDF
Research Article Muscle biology

Mesodermal iPSC–derived progenitor cells functionally regenerate cardiac and skeletal muscle

  • Text
  • PDF
Abstract

Conditions such as muscular dystrophies (MDs) that affect both cardiac and skeletal muscles would benefit from therapeutic strategies that enable regeneration of both of these striated muscle types. Protocols have been developed to promote induced pluripotent stem cells (iPSCs) to differentiate toward cardiac or skeletal muscle; however, there are currently no strategies to simultaneously target both muscle types. Tissues exhibit specific epigenetic alterations; therefore, source-related lineage biases have the potential to improve iPSC-driven multilineage differentiation. Here, we determined that differential myogenic propensity influences the commitment of isogenic iPSCs and a specifically isolated pool of mesodermal iPSC-derived progenitors (MiPs) toward the striated muscle lineages. Differential myogenic propensity did not influence pluripotency, but did selectively enhance chimerism of MiP-derived tissue in both fetal and adult skeletal muscle. When injected into dystrophic mice, MiPs engrafted and repaired both skeletal and cardiac muscle, reducing functional defects. Similarly, engraftment into dystrophic mice of canine MiPs from dystrophic dogs that had undergone TALEN-mediated correction of the MD-associated mutation also resulted in functional striatal muscle regeneration. Moreover, human MiPs exhibited the same capacity for the dual differentiation observed in murine and canine MiPs. The findings of this study suggest that MiPs should be further explored for combined therapy of cardiac and skeletal muscles.

Authors

Mattia Quattrocelli, Melissa Swinnen, Giorgia Giacomazzi, Jordi Camps, Ines Barthélemy, Gabriele Ceccarelli, Ellen Caluwé, Hanne Grosemans, Lieven Thorrez, Gloria Pelizzo, Manja Muijtjens, Catherine M. Verfaillie, Stephane Blot, Stefan Janssens, Maurilio Sampaolesi

×

Figure 6

Functional regeneration of skeletal, but not cardiac, muscles is influenced by MiP myogenic propensity.

Options: View larger image (or click on image) Download as PowerPoint
Functional regeneration of skeletal, but not cardiac, muscles is influen...
(A) WB and densitometric analyses of Sgcb protein in MiP-injected cardiac and skeletal muscle 4 weeks after injection. Consistent with the immunofluorescence data, Sgcb levels were comparable in MiP-treated myocardium samples and significantly higher in MAB-MiP–treated skeletal muscle (tibialis anterior) biopsies. n = 3/group. *P < 0.05, Mann-Whitney U test. Error bars represent SD. (B) 3D echocardiographic results showed cardiac functionality that was significantly and comparably ameliorated by f- and MAB-MiPs. (C) In contrast, the amelioration in treadmill performance (run time) and serum CK levels was markedly increased in MAB-MiP– versus f-MiP–treated mice. n = 8 mice/group. *P < 0.05 versus sham; **P < 0.05 versus sham and f-MiPs, Kruskal-Wallis and Mann-Whitney U tests. Each data point refers to 1 animal. Error bars represent average values. Accordingly, 8 weeks after injection, the absolute force measurement in EDL muscles under iterated bouts of isometric contraction showed significant improvement in the force curve in f-MiP–injected versus sham-injected mice, and in MAB-MiP– versus f-MiP–injected mice. n = 5 mice/group. #P < 0.05 versus sham; ##P < 0.05 versus sham and f-MiPs, 2-way ANOVA. Data represent average values expressed as a percentage of input sham (average value at approximately 1 for sham muscles); ribbons represent the interval of SD. (D) qPCR analysis of heart, skeletal muscles, and filter organs showed barely detectable GFP signal in liver, lungs, spleen, and kidneys 8 weeks after delivery of f- and MAB-MiPs. Immunofluorescence analysis revealed the occasional occurrence (generally ≤2 per section) of GFP+α-SMA+ small vessels in filter organs of MiP-treated animals (inset shows the spleen of an f-MiP–injected animal; n = 5 mice/cohort), suggesting very limited levels of off-target engraftment. Insets, ×40 magnification of selected areas; scale bars: ~100 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts